Anti-Mouse CTLA-4 Antibody (9H10)
Based on 1 Customer Validation
Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer.
For research use only. We do not sell to patients.
- Purity: 99%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Syrian hamster IgG
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
CTLA-4
In Vivo
Anti-Mouse CTLA-4 Antibody (9H10) (200 μg, i.p., at day 1, 4, 7) suppresses tumor growth and prolongs survival companied with radiation in 4T1 tumor mice models[2].
Anti-Mouse CTLA-4 Antibody (9H10) (200 μg, i.p., at day 14, 17, 20) inhibits primary and secondary tumor growth companied with radiation in breast and colon cancer mice models[3].
Anti-Mouse CTLA-4 Antibody (9H10) (100 μg for the first time and then two 50 μg-doses at 3-day intervals, i.p.) increases long-term survival rate and shows no experimental allergic encephalomyelitis in astrocytoma mice models[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4T1 tumor mice models[1]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, at day 15, 18, 21, companied with radiation
-
Result:Inhibited tumors and their metastases.
Reduced CFP+ 4T1 cells.
Demonstrated persistence of highly active immune effector cells.
Reversed migratory and motilityactivity elicited by each monotherapy.
-
Animal Model:4T1tumor mice models[2]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, at day 1, 4, 7, companied with radiation
-
Result:Significantly delayed the growth of the primary irradiated tumor and prolonged survival of mice.
-
Animal Model:TSA breast/MCA38 colon cancer mice models[3]
-
Dosage:200 μg
-
Administration:Intraperitoneally injection, at day 14, 17, 20, companied with radiation
-
Result:Inhibited primary and secondary tumor growth.
Increased tumor-infiltrating lymphocytes.
-
Animal Model:SMA-560 astrocytoma mice models[4]
-
Dosage:100 μg for the first time and then two 50 μg-doses at 3-day intervals
-
Administration:Intraperitoneally injection
-
Result:Elicited long-term survival in 80% of mice and no experimental allergic encephalomyelitis.
Restored CD4 numbers in all locations and Treg cells.
Reestablished a normal CD4proliferative capacity.
Enhanced proliferation and Treg resistance on CD4+CD25- T cells but does not alter Treg suppressive function.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo CTLA-4 neutralization; in vitro CTLA-4 neutralization; Western blot
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CTLA-4 Antibody (9H10)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ruocco MG, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012 Oct;122(10):3718-30. [Content Brief]
[2]. Demaria S, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34. [Content Brief]
[3]. Dewan MZ, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009 Sep 1;15(17):5379-88. [Content Brief]
[4]. Fecci PE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007 Apr 1;13(7):2158-67. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CTLA-4 Antibody (9H10) Related Classifications
HY-P990789 Related Classifications
Powered by Bioz